1 Age at Menarche and Coronary Artery Disease Risk: Divergent Associations with Different

2 Sources of Variation

- 3
- 4 Ambreen Sonawalla, MD,^{a,b} Daniel I. Chasman, PhD,^{b,c} Yee-Ming Chan, MD, PhD^{a,b}.
- ^aDivision of Endocrinology, Department of Pediatrics, Boston Children's Hospital, ^bDepartments
- 6 of Pediatrics (A.S., Y.M.C.) and Medicine (D.I.C.), Harvard Medical School, ^cDivision of
- 7 Preventive Medicine, Department of Medicine, Brigham and Women's Hospital
- 8
- 9 Short title: Age at Menarche and Coronary Artery Disease
- 10
- 11 Address for correspondence: Ambreen Sonawalla, MD;
- 12 ambreen.sonawalla@childrens.harvard.edu; 300 Longwood Avenue, Boston, MA 02115. Phone:
- 13 617-355-0796, fax: 617-730-0194.
- 14
- 15 Total word count: 7097

16 Abstract

17

Background: Both earlier and later age at menarche (AAM) are associated with increased risk

- 19 of coronary artery disease (CAD) in women. This study sought to determine if the relationship of
- AAM with CAD and CAD risk factors differs for underlying sources of variation in AAM –
- specifically, variation attributable to common genetic variants as represented by a polygenic
- score (PGS) vs. variation independent of the PGS.
- 23

24 Methods: Primary analyses were conducted on data from 201,037 women in the UK Biobank

- and validation studies on data from 23,268 women in the Women's Genome Health Study
- 26 (WGHS). For each individual, a PGS for AAM was calculated, then two variables were
- estimated from linear regression models: the PGS-associated change in AAM and the PGS-
- independent change in AAM. Logistic regression and linear splines were then used to study the
- relationships of these variables with CAD and CAD risk factors: hemoglobin A1c, triglycerides,
- 30 high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C),
- 31 systolic and diastolic blood pressure, body mass index, and waist-hip ratio.
- 32
- **Results:** PGS-associated change in AAM demonstrated a linear relationship with CAD and
- 34 linear or roughly linear relationships with CAD risk factors. In contrast, PGS-independent
- change in AAM demonstrated a U-shaped relationship with CAD and with hemoglobin A1c,
- triglycerides, HDL-C, and waist-hip ratio. Validation studies using WGHS data produced similarresults.
- 37 38
- 39 **Conclusions:** These results suggest that later AAM itself does not cause increased risk of CAD;
- 40 rather, upstream sources of variation other than common genetic variants can cause both later
- 41 AAM and increased risk of CAD. Dysglycemia, dyslipidemia, and central adiposity are
- 42 candidate mediators of the association of later AAM with increased risk of CAD.
- 43
- 44 Key words: pubertal timing, polygenic score, women, UK Biobank.

- 45 Non-standard Abbreviations and Acronyms:
- 46 AAM: age at menarche
- 47 BMI: body-mass index
- 48 CAD: coronary artery disease
- 49 DBP: diastolic blood pressure
- 50 HbA1c: hemoglobin A1c
- 51 HDL-C: high-density lipoprotein cholesterol
- 52 LDL-C: low-density lipoprotein cholesterol
- 53 PGS: polygenic score
- 54 SBP: systolic blood pressure
- 55 WGHS: Women's Genome Health Study

56 **INTRODUCTION**

57 Many pathologies manifesting in adulthood have antecedents in childhood. There is growing 58 evidence that coronary artery disease (CAD) in women, a leading cause of morbidity and 59 mortality in the world, is associated with both earlier and later age at menarche (AAM), a 60 hallmark of pubertal timing (1–4). *Earlier* puberty is associated with increased risk of CAD in 61 both men and women; however, the association between later puberty and increased risk of CAD appears to be unique to women; in men, later puberty is associated with a decreased risk of CAD 62 (3). A deeper exploration of these childhood antecedents would allow a better understanding of 63 the pathogenesis of CAD in adulthood, specifically identify factors that uniquely affect women 64 65 and facilitate the development of targeted interventions, potentially as early as childhood.

66

Multiple studies have associated earlier AAM with a higher risk of developing components of 67 the metabolic syndrome, namely obesity, type 2 diabetes mellitus, hypertension, and 68 dyslipidemia (3,5–9). Studies have further suggested that the association between earlier AAM 69 and risk of CAD is mediated by adiposity (10,11). In contrast, the associations of later AAM 70 reported to date do not fit neatly into the paradigm of metabolic syndrome. Later AAM is 71 72 associated with lower rather than higher body-mass index (BMI) (3,12,13), and studies on other components of the metabolic syndrome have produced conflicting results, with some studies 73 74 showing association of later AAM with higher risk of hypertension (1,14), others showing a 75 lower risk of hypertension (3) or type 2 diabetes (15), and yet others showing no association with 76 hypertension, type 2 diabetes, or hypercholesterolemia (3,16). Hence, while earlier AAM has 77 been associated with several CAD risk factors, there may be distinct mechanisms underlying the 78 association of later AAM with increased risk of CAD.

79

80	Variation in AAM can stem from several upstream sources, including genetics (both common
81	genetic variants and rare genetic variants), acquired factors such as chronic illness, chronic
82	stress, underweight, and undernutrition, and environmental factors such as family composition
83	(17). It is possible that some of these sources of variation may influence risk of CAD only
84	through their influence on AAM, while others may directly influence CAD risk and features of
85	the metabolic syndrome (Figure 1). Thus, dissecting variation in AAM based on underlying
86	sources of variation could provide a clearer understanding of the relationship of AAM with
87	CAD.
88	

Genetics is a major source of variation in AAM, with half to three-quarters of variation
attributable to genetics (18,19). The largest published genome-wide association study (GWAS)
on AAM identified 389 independent single-nucleotide polymorphisms (SNPs) associated with
AAM at genome-wide significance. The results from this GWAS allow the calculation of a
polygenic score (PGS) for a given individual to reflect the cumulative contribution of common
genetic variants to AAM.

95

Previous studies have used PGSs to dissect the influence of genetics vs. environmental factors
(or other factors not captured by the PGS) that contribute to traits such as BMI and LDL-C
(20,21). These studies have found that associations of these traits with health outcomes differ
between genetically and environmentally influenced traits. For example, obesity driven by
environmental factors was associated with more harmful cardiovascular outcomes than

101	genetically predicted obesity (20), suggesting that dissecting effects based on underlying source
102	of variation can allow deeper insights into pathogenic mechanisms.

103

- 104 The aims of this study were two-fold: first, to determine if the association between later AAM
- and increased risk of CAD depends on the underlying source of variation in AAM specifically,
- 106 common genetic variation vs. other sources of variation; second, to study the relationships of
- 107 these different sources of variation in AAM with CAD risk factors.

108

109 METHODS

- 110 To study how different sources of variation in the timing of menarche affect risk of CAD,
- 111 variation in AAM was subdivided into variation attributable to the effects of common genetic
- 112 influences, as estimated by a PGS for AAM, and variation due to other sources, i.e., independent

of the PGS.

114

115 *Study cohorts*

116 This study used data from two cohorts: the UK Biobank for primary analyses and the Women's

117 Genome Health Study (WGHS) for validation analyses. The UK Biobank is a population-based

118 cohort of over 500,000 men and women in the UK 40 years and older at the time of recruitment,

- 119 with extensive health-related phenotypic and laboratory data as well as individual-level genetic
- data (22). This study analyzed data from 201,037 unrelated women in the UK Biobank of non-
- 121 Finnish European ancestry (as determined through principal component analysis) (23) who had

122	genetic and self-reported AAM data. During data collection in the UK Biobank, any value of
123	AAM <5 years or >25 years was rejected, and any AAM entered as <6 years or >20 years
124	required confirmation from participants (24). Women with missing AAM data were excluded
125	from analysis. The UK Biobank obtained the multiple ethical and regulatory approvals required
126	for recruitment and research procedures, and participants provided written consent (22). The
127	WGHS is a cohort of initially healthy American women aged 45 years and older at enrollment
128	with genetic and phenotypic data, followed over 26-28 years for cardiovascular and other
129	outcomes (25). This analysis studied data from 23,268 women in the WGHS who had genetic
130	and self-reported AAM data. Self-reported AAM ≤ 9 years or ≥ 17 years were entered as 9 years
131	or 17 years, respectively. The WGHS was approved by the institutional review board of Brigham
132	and Women's Hospital, and participants consented to ongoing analyses (25).

133

134 *Polygenic score calculation*

135 A PGS was calculated for each woman in the above cohorts in two steps. The first step used the PRS-CS algorithm, which allows the inclusion of all available SNPs from the GWAS on AAM 136 (26), not just those that meet a given *p*-value threshold, and weights the SNP effect sizes based 137 on their significance and adjusts for linkage disequilibrium (27). The use of this algorithm has 138 the potential to explain more variability in AAM than algorithms that use only the SNPs that 139 meet a given significance threshold. The second step calculated the PGS using PRSice-2 140 (without clumping or thresholding) to sum the weighted effect sizes for all SNPs in each 141 individual with the ability to incorporate the probabilistic genotype dosages generated by 142 143 imputation (28).

144

145 Subdividing variation in age at menarche

Using each full cohort, regression of self-reported AAM was performed against the PGS for
AAM, with the first 10 genetic principal components, assessment center and technical variables
such as array number as covariates. The following two variables were then calculated for each
individual:

150	1.	PGS-associated change in AAM (PGS-associated ΔAAM): This represents the change in
151		AAM attributable to the contributions of common genetic variants as estimated by the
152		PGS. This was calculated as the difference between the individual's AAM predicted by
153		the regression and the AAM corresponding to the mean PGS for the cohort
154		(Supplemental Figure 1).
155	2.	PGS-independent change in AAM (PGS-independent ΔAAM): This represents the
156		change in AAM attributable to sources of variation not represented by the PGS. This was
157		the residual for the individual of the regression of AAM against the PGS (Supplemental
158		Figure 1).
159		

160 *Outcomes and analytical methods*

161 The study's primary outcome variable was CAD risk. In the UK Biobank, prevalent CAD at

baseline was determined as previously described using a combination of self-report, ICD-9/10

163 codes, and procedure codes (23). The WGHS recruited women with no history of CAD at

baseline and identified validated incident CAD during 26-28 years of follow-up as described

165 previously (25). Secondary outcome variables were CAD risk factors at baseline for both

166	cohorts: hemoglobin A1c (HbA1c), triglycerides, high-density lipoprotein cholesterol (HDL-C),
167	low-density lipoprotein cholesterol (LDL-C), systolic blood pressure (SBP), diastolic blood
168	pressure (DBP), and BMI; data on waist-hip ratio was available at baseline in the UK Biobank
169	and 6 years after recruitment in the WGHS.
170	
171	The relationships of PGS-associated ΔAAM and PGS-independent ΔAAM with CAD prevalence
172	were studied using logistic regression, with incident CAD using Cox proportional hazards
173	models, and with each continuous variable (HbA1c, triglycerides, HDL-C, LDL-C, SBP, DBP,
174	BMI, waist-hip ratio) using linear splines, with a knot at ΔAAM of 0 years. For analyses with
175	LDL-C, results were corrected for self-reported use of cholesterol-lowering medications – these

176 were specific LDL-lowering medications in the UK Biobank, (statins, ezetimibe, and bile-acid

sequestrants) and collective cholesterol-lowering medications in the WGHS; additional analyses

178 included only women not taking these medications.

179 Covariates of age and age² were used for all analyses. Analyses were conducted using R v.4.3.1.
180 A significance threshold of 0.05 was used.

181

To determine if results in the UK Biobank were biased by overfitting as a result of the UK
Biobank having contributed to the GWAS for AAM, we also repeated analyses of CAD using a
PGS calculated using an earlier GWAS that did not include the UK Biobank (29). Furthermore,
to determine if outlier values of AAM were disproportionately affecting results, analyses were
repeated after excluding women with extreme values of AAM such that up to 0.1% of women
were excluded at each extreme.

188

189 **RESULTS**

- 190 To study the relationship between AAM and CAD risk, our study divided variation in AAM into
- 1) variation attributable to the effects of common genetic variants as estimated by a PGS for
- 192 AAM, which we term PGS-associated Δ AAM, and 2) variation due to factors not captured by the
- 193 PGS, which we term PGS-independent ΔAAM .

194

195 To examine the differential effects of these two sources of variation on CAD risk, we analyzed

data from 201,037 unrelated, non-Finnish European women in the UK Biobank. We first

197 calculated a PGS for AAM for each woman, then regressed self-reported AAM against the AAM

198 PGS to calculate PGS-associated $\triangle AAM$ and PGS-independent $\triangle AAM$ (Supplemental Figure 1).

199 For women in the UK Biobank, the regression of self-reported AAM against the AAM PGS

200 demonstrated that the PGS accounted for 15.8% of the variation in AAM. PGS-associated

 ΔAAM had a mean of 0.016 years, with a standard deviation of 0.639 years, and the residual,

202 PGS-independent ΔAAM , had a mean of 0 years with a standard deviation of 1.47 years

203 (Supplemental Figure 2). We then studied the associations of PGS-associated ΔAAM and PGS-

independent $\triangle AAM$ with risk of CAD and with CAD risk factors.

205

206 *Risk of coronary artery disease*

207 Risk of CAD demonstrated a linear relationship with PGS-associated ΔAAM but a non-linear,

208 U-shaped relationship with PGS-independent ΔAAM (Figure 2). In the linear relationship of

209	PGS-associated ΔAAM with risk of CAD; each 1-year increase in PGS-associated ΔAAM was
210	associated with an odds ratio (OR) for CAD of 0.91. In other words, for every 1 year that AAM
211	was later due to the effects of common genetic variants, as estimated by the PGS, the odds of
212	CAD were lower by 9% (Table 1). Linear spline analyses showed no difference in slopes when
213	PGS-associated $\triangle AAM$ was negative vs. positive, i.e., driving earlier vs. later AAM (Table 1).
214	
215	In contrast, the association between PGS-independent ΔAAM and risk of CAD was U-shaped,
216	with both increasingly negative and increasingly positive values (driving earlier and later AAM,
217	respectively) associated with increased CAD risk (Figure 2). For negative values of PGS-
218	independent ΔAAM , each 1-year increase (causing AAM to be less early) was associated with an
219	OR for CAD of 0.91 (Table 1). In other words, for every 1 year that AAM was less early due to
220	factors independent of the PGS, the odds of CAD were lower by 9%. In contrast, for positive
221	values of PGS-independent ΔAAM , each 1-year increase (causing AAM to be even later) was
222	associated with an OR for CAD of 1.11, i.e., the odds of CAD were higher by 11% (Table 1).
223	
224	Because the 2018 AAM GWAS meta-analysis included data from the UK Biobank, which could
225	introduce bias in the above analyses, we conducted sensitivity analyses using the results from an
226	AAM GWAS meta-analysis published in 2014 that did not include the UK Biobank. These
227	analyses showed similar results for CAD (Supplemental Figure 3, Supplemental Table 1). We
228	also conducted sensitivity analyses excluding women with extreme values of AAM and obtained
229	similar results.

230

231 *Hemoglobin A1c*

We then examined the associations of PGS-associated ΔAAM and PGS-independent ΔAAM with CAD risk factors. Just as the relationship between PGS-associated ΔAAM and CAD was linear, we observed linear (or roughly linear) relationships between PGS-independent ΔAAM and most CAD risk factors. In contrast, for PGS-independent ΔAAM we observed mostly nonlinear relationships with CAD risk factors.

237

For hemoglobin A1c, which correlates with average blood glucose over the preceding 3 months,

239 PGS-associated ΔAAM demonstrated a roughly negative linear relationship, with higher PGS-

associated ΔAAM associated with lower HbA1c (Figure 3). The slope of the association with

241 HbA1c for negative values of PGS-associated ΔAAM was slightly steeper than for positive

values ((-0.034 and -0.022, respectively; p for difference between slopes: 7×10^{-5} ; Table 1). In

243 contrast, PGS-independent $\triangle AAM$ demonstrated a U-shaped relationship with HbA1c: both

increasingly negative and increasingly positive values of PGS-independent ΔAAM were

associated with an increase in HbA1c (for negative values: slope = -0.022, for positive values:

slope = 0.007; *p* for difference between slopes $< 2 \ge 10^{-16}$; Figure 3, Table 1). This was similar

to the U-shaped relationship of PGS-independent ΔAAM with CAD risk.

248

Comparing PGS-associated ΔAAM and PGS-independent ΔAAM, for negative values (driving
earlier AAM) the slopes for the associations with HbA1c were comparable. However, for
positive values (driving later AAM), different slopes were seen for PGS-associated vs. PGS-

252	independent ΔAAM ; as noted above, for every 1 year that AAM was delayed, HbA1c <i>decreased</i>
253	by 0.01% for PGS-associated ΔAAM but <i>increased</i> by 0.007% for PGS-independent ΔAAM .

254

255 Lipids

256	PGS-associated ΔAAM demonstrated linear relationships with triglycerides and HDL-C (Figure
257	3), with higher values of PGS-associated ΔAAM associated with a decrease in triglycerides and
258	an increase in HDL-C (Figure 3) and no significant difference in slopes between negative and
259	positive values of PGS-associated $\triangle AAM$ (<i>p</i> for difference in slopes for triglycerides = 0.83, for
260	HDL-C = 0.38; Table 1). In contrast, PGS-independent $\triangle AAM$ demonstrated non-linear
261	relationships with HDL-C and triglycerides – U-shaped for triglycerides and inverted-U-shaped
262	for HDL-C (Figure 3), with both increasingly negative and increasingly positive values of PGS-
263	independent ΔAAM associated with increases in triglycerides and decreases in HDL-C (Figure 3,
264	Table 1).
265	
266	For LDL-C, PGS-associated ΔAAM showed no association for negative values of PGS-
267	associated ΔAAM and a negative linear relationship for positive values of PGS-associated
268	ΔAAM (Table 1). For PGS-independent ΔAAM , there was an association for negative values –
269	increasing PGS-independent ΔAAM was associated with lower LDL-C – and no significant
270	association with LDL-C for positive values of PGS-independent ΔAAM (Figure 3, Table 1).
271	Similar results were seen when analyses excluded those taking LDL-lowering medications
272	(Table 1).

273

274 Blood pressure

275	For PGS-associated ΔAAM , increasing PGS-associated ΔAAM was associated with decreases in
276	both SBP and DBP (Figure 3), with no significant difference between the slopes for negative vs.
277	positive values of PGS-associated ΔAAM (Table 1). For PGS-independent ΔAAM , increasing
278	PGS-independent ΔAAM was also associated with decreased SBP and DBP (Figure 3), but the
279	slopes of the associations were steeper for negative values of PGS-independent ΔAAM
280	compared to the slopes for positive values of PGS-independent ΔAAM (Table 1).
281	
282	Adiposity
283	We studied two estimates of adiposity: BMI and waist-hip ratio. For BMI, we found a roughly
284	linear negative relationship between PGS-associated ΔAAM and BMI, with higher PGS-
285	associated $\triangle AAM$ associated with lower BMI (Figure 3, Table 1). The slope of the association

with BMI was slightly steeper for negative values of PGS-associated ΔAAM than for positive

values (Table 1). This pattern was similar to the relationship seen between PGS-associated

288 $\triangle AAM$ and HbA1c.

289

290 For PGS-independent ΔAAM , a reverse-J-shaped relationship was seen with BMI (Figure 3).

291 While higher values of PGS-independent ΔAAM were consistently associated with lower BMI,

- the slope of the association was ten-fold steeper for negative than for positive values of PGS-
- independent ΔAAM (-0.80 vs. -0.079 respectively; *p* for difference between slopes 2 x 10⁻¹⁶;

Table 1). This resembled the patterns seen with SBP and DBP.

296	For waist-hip ratio, PGS-associated ΔAAM showed a negative linear association, with no
297	significant difference in slopes for the association when PGS-associated ΔAAM was negative vs.
298	positive (Figure 3, Table 1). In contrast, the relationship of PGS-independent ΔAAM with waist-
299	hip ratio was U-shaped, with both increasingly negative and increasingly positive values of PGS-
300	associated $\triangle AAM$ associated with an increase in waist-hip ratio (Figure 3, Table 1), similar to
301	the associations seen with CAD, HbA1c, triglycerides, and HDL-C.
302	
303	Validation in the Women's Genome Health Study
304	Validation studies using data from the WGHS produced results similar to the above results for
305	the UK Biobank. In the WGHS, PGS-associated ΔAAM showed linear relationships with
306	HbA1c, triglycerides, HDL-C, SBP, DBP, BMI and waist-hip ratio and no clear relationship with
307	LDL-C (Figure 4). Just as in the UK Biobank, PGS-independent ΔAAM showed U-shaped
308	relationships with triglycerides and HbA1c, an inverted-U-shaped relationship with HDL-C, and

a reverse-J-shaped relationship with BMI in the WGHS (Figure 4).

310

311 There were two differences between results from the WGHS and the UK Biobank: 1) for SBP

and DBP, PGS-independent ΔAAM showed roughly U-shaped relationships in the WGHS

313 (Figure 4) rather than the reverse-J-shaped relationships seen in the UK Biobank (Figure 3), and

2) for waist-hip ratio, PGS-independent ΔAAM showed a negative linear relationship for

negative values of PGS-independent ΔAAM but no significant relationship for positive values in

the WGHS (Figure 4) compared to the clear U-shaped relationship seen in the UK Biobank

317 (Figure 2).

318

325	DISCUSSION
324	
323	Table 1), slightly different from the U-shaped relationship seen in the UK Biobank.
322	analyses in the WGHS demonstrated a reverse-J shaped relationship (Figure 5, Supplemental
321	relationship in both cohorts. For the relationship of PGS-independent ΔAAM with CAD,
320	similar to that in the UK Biobank (Figure 5, Supplemental Table 1), with a negative linear
319	For risk of CAD itself, the relationship of PGS-associated ΔAAM with CAD in the WGHS was

In this study, we dissected variation in AAM into variation attributable to common genetic variants, as estimated by a PGS, and variation independent of the PGS, and we found different relationships with these two sources of variation in AAM with risk of CAD and with CAD risk factors, particularly when causing AAM to occur later.

330

In general, later AAM showed favorable associations when attributable to PGS-associated 331 variation and harmful or neutral associations when attributable to PGS-independent variation. If 332 all sources of variation were affecting CAD and CAD risk factors wholly through AAM itself, 333 the associations would be similar regardless of the source of variation studied. Our finding that 334 335 these associations varied based on the underlying source of variation driving later AAM therefore indicates that it is not later AAM itself that causes increased risk of CAD. Rather, there 336 appear to be PGS-independent factors that cause both later AAM and increased risk of CAD and 337 338 unfavorable cardiometabolic risk profiles. Such factors could include environmental or acquired influences (such as chronic illnesses, chronic stress, undernutrition) as well as genetic influences 339

not captured by the PGS, and future studies will identify these factors and determine how theycontribute to CAD risk.

342

Earlier AAM, whether attributable to PGS-associated or PGS-independent sources of variation, 343 was consistently associated with greater cardiometabolic risk. Thus, it seems that earlier AAM 344 itself is intrinsically associated with risk for CAD and worsening CAD risk factors; indeed, some 345 Mendelian randomization studies suggest that earlier AAM is causative of these negative 346 347 outcomes (10,11,30). However, other Mendelian randomization studies have suggested that the association of earlier AAM and increased risk of CAD is due to pleiotropic effects of genetic 348 factors influencing both AAM and BMI, such that AAM itself may have only a small influence 349 350 (31).

351

352 The U-shaped relationship of PGS-independent $\triangle AAM$ with CAD was mirrored by the relationships with HbA1c, triglycerides, HDL-C, and waist-hip ratio. This raises the possibility 353 that dysglycemia, dyslipidemia, and central adiposity contribute to the relationship between later 354 355 AAM and increased risk of CAD; further studies will be required to formally evaluate these CAD risk factors as potential mediators of this relationship. As noted above, previous studies 356 evaluating associations of later AAM with these CAD risk factors have had conflicting results. 357 While differences between study cohorts may have accounted for some of the differing results, 358 359 our findings raise the additional possibility that the relationships between later AAM and these 360 outcomes may have been obscured by opposing effects of PGS-associated and PGS-independent variation in AAM. Of note, the associations with waist-hip ratio differed from those with BMI, 361

suggesting that central obesity, reflected by waist-hip ratio, is more relevant for CAD, as hasbeen suggested by prior studies (32,33).

364

Our analyses in the Women's Genome Health Study (WGHS) largely validated our results from the UK Biobank. PGS-associated change in AAM demonstrated linear relationships with CAD and CAD risk factors, and PGS-independent change in AAM demonstrated mostly non-linear relationships with these outcomes, supporting the conclusions described earlier.

369

370 However, the two cohorts also demonstrated some differences, most notably in the association of 371 PGS-independent ΔAAM with the risk of CAD and waist-hip ratio In the UK Biobank, PGSindependent variation driving AAM later was associated with an increased risk of CAD, but 372 there was no association in the WGHS. For waist-hip ratio, PGS-independent variation 373 374 demonstrated a clear U-shaped association in the UK Biobank but a reverse J-shaped relationship in the WGHS. There are several potential reasons for this difference. First, it is possible that the 375 smaller sample size and lower power in the WGHS affected the ability to find significant 376 associations with PGS-independent variation in AAM and risk of CAD and waist-hip ratio. 377 Second, environmental influences affecting AAM (which would contribute to PGS-independent 378 variation in AAM) could differ between the two cohorts. The WGHS recruited women in the 379 United States of America born in 1950 or earlier, while the UK Biobank recruited women in the 380 UK who were born between 1932 and 1969. The different impact of global events such as World 381 War II on the two countries could contribute to differences in the PGS-independent factors 382 (which includes environmental factors) and, in turn, to different associations with risk of CAD. 383

384 Third, the WGHS excluded women with a history of CAD at the time of enrollment whereas the UK Biobank did not, and this may also have led to differences in PGS-independent factors 385 between the cohorts. Fourth, the participants in the WGHS were health professionals while the 386 UK Biobank drew from the general UK population, and this may have led to further differences 387 in PGS-independent factors, such as higher socioeconomic status, greater knowledge of CAD 388 389 and its risk factors, healthier diets and lifestyles, and use of preventative interventions, as well as potentially less variation in these factors.. While the analyses also differed in the CAD measure 390 used from each cohort – prevalence of CAD was analyzed in the UK Biobank compared to 391 392 incidence of CAD in the WGHS – it is unlikely to account for the difference in results, as an analysis of incident CAD in the Million Women Study in the UK also showed a U-shaped 393 relationship between AAM and CAD (1). Despite these differences in the results between the 394 two cohorts, results from both cohorts consistently demonstrated differences between the 395 associations of PGS-independent variation driving AAM earlier (negative values) vs. driving 396 397 AAM *later* (positive values) with these outcomes.

398

In 2021, Liang et al. used a PGS to represent genetically predicted AAM and examined associations with all-cause mortality, also using data from the UK Biobank. Interestingly, they found a U-shaped association with mortality, with both earlier and later genetically predicted AAM associated with higher risk; this finding contrasts with the linear relationship we found between PGS-associated Δ AAM and CAD. This difference suggests that later genetically predicted AAM increases the risk of causes of mortality other than CAD, and future studies of genetically predicted AAM are needed to identify these causes.

406

407	Prior studies that have also dissected influences on human traits into genetic vs. environmental
408	influences have found differences in the magnitude of effect of genetics vs. environmental
409	influences on health outcomes (20,21). Interestingly, our results show not only different
410	magnitudes of influence of PGS-associated and PGS-independent variation in AAM on risk of
411	CAD, but also opposite directionality. This further underscores the value of separating the effects
412	of genetics vs. other influences while studying human traits as they can have starkly different
413	effects.
414	
415	Sensitivity analyses using a GWAS that did not include the primary cohort, the UK Biobank,
416	produced similar results and suggested that these results were not biased by overfitting.
417	Additionally, sensitivity analyses excluding women with extreme values of AAM also produced
418	similar results, suggesting that results were not heavily influenced by outliers.
419	
420	One limitation of this study is that while the PGS represents genetic influences on AAM, it does
421	not represent all genetic factors that influence AAM. Our analyses demonstrated that the PGS
422	explains 15.8% of the variation in the observed AAM, but prior studies suggest that 49-73% of

423 variation in AAM is inherited (18,19); hence, a large amount of the variation in AAM due to

424 genetic factors remains unexplained. Another limitation of this study is that the PGS represents

just one method of capturing the effects of common genetic variants that affect AAM. There may

426 be several pathways causing later AAM represented within these common genetic variants, and

427 using a single PGS to represent all those effects may obscure relationships with each individual

428 pathway. Future studies may identify these different pathways by methods such as clustering

429	analyses (34,35), which would then allow an estimation of multiple polygenic scores, each
430	representing a different pathway, to study their associations with risk of CAD and CAD risk
431	factors.

433	Distinguishing between source	s of variation in AAM has	provided a novel lens	through which to

- 434 study associations of AAM with CAD and has allowed us to uncover differences in the
- 435 associations of PGS-associated vs. PGS-independent variation in AAM with CAD and CAD risk
- 436 factors. Because later puberty in women, but not men, has been associated with an increased risk
- 437 of CAD, studying these differences further may provide unique insights into mechanisms that
- 438 affect CAD risk specifically in women.

439 ACKNOWLEDGEMENTS

440 The authors thank Evan Schafer and Jia Zhu for their support with statistical analyses. This

- 441 research has been conducted using data from UK Biobank, a major biomedical database:
- 442 <u>www.ukbiobank.ac.uk</u>

443 SOURCES OF FUNDING

444 A.S. was supported by National Institutes of Health (NIH) grant T32DK007699. The WGHS and

its parent cohort, the Women's Health Study (WHS), have been supported by the National Heart,

Lung, and Blood Institute (HL043851 and HL080467) and the National Cancer Institute

447 (CA047988 and UM1CA182913), with support and funding for genotyping provided by Amgen.

448 Some cardiovascular endpoints in the WHS were funded by HL099355.

449 DISCLOSURES

- 450 A.S. has no disclosures or relationships with industry. D.I.C has no disclosures or relationships
- 451 with industry. Y.-M.C. receives royalties from UpToDate on topics related to puberty.
- 452
- 453
- 454 SUPPLEMENTAL MATERIALS
- 455 Supplemental Figures 1-3
- 456 Supplemental Table 1

457 **REFERENCES**

458 459	1.	Canoy D, Beral V, Balkwill A, Wright FL, Kroll ME, Reeves GK, et al. Age at menarche and risks of coronary heart and other vascular diseases in a large UK cohort. Circulation 2015;131(3):237–44.
460		
461 462	2.	Zhu J, Chan YM. Adult Consequences of Self-Limited Delayed Puberty. Pediatrics [Internet]. 2017 Jun 1;139(6).
463		
464 465 466	3.	Day FR, Elks CE, Murray A, Ong KK, Perry JRB. Puberty timing associated with diabetes, cardiovascular disease and also diverse health outcomes in men and women: the UK Biobank study. Sci Rep. 2015 Jun 18;5.
467		
468 469 470 471	4.	Lee JJ, Cook-Wiens G, Johnson BD, Braunstein GD, Berga SL, Stanczyk FZ, et al. Age at Menarche and Risk of Cardiovascular Disease Outcomes: Findings From the National Heart Lung and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation. J Am Heart Assoc. 2019 Jun 18;8(12).
472		
473 474 475	5.	Santos MP, Li Y, Bazzano LA, He J, Rexrode KM, Ley SH. Age at menarche, type 2 diabetes and cardiovascular disease complications in US women aged under 65 years: NHANES 1999-2018. BMJ Nutr Prev Health. 2023 Dec 1;6(2):293–300.
476		
477 478	6.	Janghorbani M, Mansourian M, Hosseini E. Systematic review and meta-analysis of age at menarche and risk of type 2 diabetes. Acta Diabetol. 2014;51(4):519–28.
479		
480 481 482	7.	Stöckl D, Meisinger C, Peters A, Thorand B, Huth C, Heier M, et al. Age at menarche and its association with the metabolic syndrome and its components: results from the KORA F4 study. PLoS One. 2011 Oct 18;6(10).
483		
484 485	8.	Liu D, Qin P, Liu Y, Sun X, Li H, Wu X, et al. Association of age at menarche with hypertension in rural Chinese women. J Hypertens. 2021 Mar 1;39(3):476–83.
486		
487 488 489	9.	Kheradmand M, Hamzehgardeshi Z, Shahhosseini Z, Mirjalili R, Moosazadeh M. The association between early menarche and higher-risk cardiometabolic profile: a dose-response analysis of the Tabari cohort at enrollment phase. Front Cardiovasc Med. 2023;10.
490		

491 492	10.	Cao M, Cui B. Negative Effects of Age at Menarche on Risk of Cardiometabolic Diseases in Adulthood: A Mendelian Randomization Study. J Clin Endocrinol Metab. 2020 Jan 23;105(2).
493		
494 495 496	11.	Gill D, Brewer CF, Del Greco M F, Sivakumaran P, Bowden J, Sheehan NA, et al. Age at menarche and adult body mass index: a Mendelian randomization study. International Journal of Obesity 2018 42:9. 2018 Feb 26;42(9):1574–81.
497		
498 499	12.	Prentice P, Viner RM. Pubertal timing and adult obesity and cardiometabolic risk in women and men: a systematic review and meta-analysis. Int J Obes (Lond). 2013 Aug;37(8):1036–43.
500		
501 502 503	13.	Yang L, Li L, Millwood IY, Lewington S, Guo Y, Sherliker P, et al. Adiposity in relation to age at menarche and other reproductive factors among 300 000 Chinese women: findings from China Kadoorie Biobank study. Int J Epidemiol. 2017 Jan 1;46(2):502–12.
504		
505 506 507	14.	Chen L, Zhang L, Chen Z, Wang X, Zheng C, Kang Y, et al. Age at menarche and risk of hypertension in Chinese adult women: Results from a large representative nationwide population. J Clin Hypertens (Greenwich). 2021 Aug 1;23(8):1615–21.
508		
509 510	15.	Liu D, Zhao Y, Liu Y, Sun X, Li H, Yin Z, et al. Adiposity and insulin resistance as mediators between age at menarche and type 2 diabetes mellitus. Menopause. 2020 May 1;27(5):579–85.
511		
512 513	16.	Elks CE, Ong KK, Scott RA, Van Der Schouw YT, Brand JS, Wark PA, et al. Age at menarche and type 2 diabetes risk: the EPIC-InterAct study. Diabetes Care. 2013 Nov;36(11):3526–34.
514		
515 516	17.	Schlomer GL, Marceau K. Father absence, age at menarche, and genetic confounding: A replication and extension using a polygenic score. Dev Psychopathol. 2022 Feb 27;34(1):355–66.
517		
518 519 520	18.	Morris DH, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Familial concordance for age at menarche: Analyses from the breakthrough generations study. Paediatr Perinat Epidemiol. 2011 May;25(3):306–11.
521		
522 523	19.	Towne B, Czerwinski SA, Demerath EW, Blangero J, Roche AF, Siervogel RM. Heritability of age at menarche in girls from the Fels Longitudinal Study. Am J Phys Anthropol. 2005 Sep;128(1):210–9.
524		

525 526 527	20.	Ojalehto E, Zhan Y, Jylhävä J, Reynolds CA, Dahl Aslan AK, Karlsson IK. Genetically and environmentally predicted obesity in relation to cardiovascular disease: a nationwide cohort study. EClinicalMedicine. 2023 Apr 1;58.
528		
529 530 531	21.	Hawkes G, Yengo L, Vedantam S, Marouli E, Beaumont RN, Tyrrell J, et al. Identification and analysis of individuals who deviate from their genetically-predicted phenotype. PLoS Genet. 2023 Sep 21;19(9).
532		
533 534 535	22.	Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015 Mar 1;12(3).
536		
537 538 539	23.	Zhu J, Pujol-Gualdo N, Wittemans LBL, Lindgren CM, Laisk T, Hirschhorn JN, et al. Evidence From Men for Ovary-independent Effects of Genetic Risk Factors for Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2022 Mar 24;107(4):e1577–87.
540		
541 542	24.	UK Biobank age at menarche data collection: https://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=2714.
543		
544 545 546	25.	Ridker PM, Chasman DI, Zee RYL, Parker A, Rose L, Cook NR, et al. Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy american women. Clin Chem. 2008;54(2):249–55.
547		
548 549 550	26.	Day FR, Thompson DJ, Helgason H, Chasman DI, Finucane H, Sulem P, et al. Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. Nat Genet. 2017 Jun 1;49(6):834.
551		
552 553	27.	Ge T, Chen CY, Ni Y, Feng YCA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat Commun. 2019 Dec 1;10(1).
554		
555 556	28.	Choi SW, O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data. Gigascience. 2019 Jul 1;8(7).
557		
558 559	29.	Perry JRB, Day F, Elks CE, Sulem P, Thompson DJ, Ferreira T, et al. Parent-of-origin specific allelic associations among 106 genomic loci for age at menarche. Nature. 2014 Oct 10;514(7520):97.
560		

30. Zheng J, Chen K, Huang T, Shao C, Li P, Wang J, et al. Genetically Determined Lifestyle and
Cardiometabolic Risk Factors Mediate the Association of Genetically Predicted Age at Menarche
With Genetic Predisposition to Myocardial Infarction: A Two-Step, Two-Sample Mendelian
Randomization Study. Front Cardiovasc Med. 2022 Apr 25;9.

565

566 31. Bell JA, Carslake D, Wade KH, Richmond RC, Langdon RJ, Vincent EE, et al. Influence of puberty
567 timing on adiposity and cardiometabolic traits: A Mendelian randomisation study. PLoS Med.
568 2018 Aug 1;15(8).

569

Huxley R, Mendis S, Zheleznyakov E, Reddy S, Chan J. Body mass index, waist circumference and
 waist:hip ratio as predictors of cardiovascular risk--a review of the literature. Eur J Clin Nutr. 2010
 Jan;64(1):16–22.

573

Sahakyan KR, Somers VK, Rodriguez-Escudero JP, Hodge DO, Carter RE, Sochor O, et al. NormalWeight Central Obesity: Implications for Total and Cardiovascular Mortality. Ann Intern Med.
2015 Dec 1;163(11):827–35.

577

S78 34. Chasman DI, Giulianini F, Demler O V., Udler MS. Pleiotropy-Based Decomposition of Genetic Risk
Scores: Association and Interaction Analysis for Type 2 Diabetes and CAD. Am J Hum Genet. 2020
May 7;106(5):646–58.

581

35. Udler MS, Kim J, von Grotthuss M, Bonàs-Guarch S, Cole JB, Chiou J, et al. Type 2 diabetes genetic
loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft
clustering analysis. PLoS Med. 2018 Sep 1;15(9).

585

587 FIGURE LEGENDS

589	Figure 1: Relationships of different sources of variation in age at menarche (AAM) with
590	coronary artery disease (CAD) and CAD risk factors. Variation in AAM was dissected into
591	variation associated with common genetic variants (as estimated by a polygenic score for AAM)
592	and variation independent of the polygenic score, then associations of these sources of variation
593	with CAD and CAD risk factors were studied. When associated with common genetic variants,
594	later AAM was associated with a lower risk of CAD and favorable changes in CAD risk factors
595	(blue arrows). However, when occurring independently of the polygenic score, later AAM was
596	associated with higher risk of CAD and unfavorable changes in CAD risk factors (red arrows).
597	The "other factors" causing later AAM independent of the PGS have yet to be identified and
598	could potentially include chronic illness, underweight, and rare genetic variants.
599	
599 600	Figure 2: Association of variation in AAM with odds of CAD in the UK Biobank. Variation
	Figure 2: Association of variation in AAM with odds of CAD in the UK Biobank. Variation in AAM was dissected into variation associated with common genetic variants as estimated by a
600	
600 601	in AAM was dissected into variation associated with common genetic variants as estimated by a
600 601 602	in AAM was dissected into variation associated with common genetic variants as estimated by a PGS for AAM (PGS-associated Δ AAM) and variation independent of the PGS (PGS-
600 601 602 603	in AAM was dissected into variation associated with common genetic variants as estimated by a PGS for AAM (PGS-associated Δ AAM) and variation independent of the PGS (PGS-independent Δ AAM), then associations of these sources of variation with risk of CAD were
600 601 602 603 604	in AAM was dissected into variation associated with common genetic variants as estimated by a PGS for AAM (PGS-associated Δ AAM) and variation independent of the PGS (PGS-independent Δ AAM), then associations of these sources of variation with risk of CAD were studied. PGS-associated Δ AAM showed linear or roughly linear associations with CAD whereas
600 601 602 603 604 605	in AAM was dissected into variation associated with common genetic variants as estimated by a PGS for AAM (PGS-associated Δ AAM) and variation independent of the PGS (PGS- independent Δ AAM), then associations of these sources of variation with risk of CAD were studied. PGS-associated Δ AAM showed linear or roughly linear associations with CAD whereas PGS-independent Δ AAM showed a U-shaped association with risk of CAD. The different
600 601 602 603 604 605 606	in AAM was dissected into variation associated with common genetic variants as estimated by a PGS for AAM (PGS-associated Δ AAM) and variation independent of the PGS (PGS- independent Δ AAM), then associations of these sources of variation with risk of CAD were studied. PGS-associated Δ AAM showed linear or roughly linear associations with CAD whereas PGS-independent Δ AAM showed a U-shaped association with risk of CAD. The different associations of positive values of PGS-associated Δ AAM with risk of CAD demonstrates that it

- group of individuals with $\Delta AAM \leq or \geq$ the value listed on the x-axis, respectively. Dots 610
- 611 represent estimates; bars represent standard errors.

- 612 AAM: age at menarche; \triangle AAM: change in AAM; CAD: coronary artery disease; PGS:
- 613 polygenic score.

615	Figure 3: Associations of variation in AAM with risk factors for CAD in the UK Biobank.
616	We observed linear (or roughly linear) relationships between PGS-associated ΔAAM and most
617	CAD risk factors. In contrast, for PGS-independent ΔAAM we observed mostly non-linear
618	relationships with CAD risk factors. The U-shaped relationship of PGS-independent ΔAAM with
619	CAD was mirrored by the relationships with HbA1c, triglycerides, HDL-C, and waist-hip ratio.
620	This raises the possibility that dysglycemia, dyslipidemia and central adiposity may mediate the
621	relationship between later AAM and increased risk of CAD. For LDL-C, n = 177,542 after
622	excluding those taking LDL-C lowering medications. Dots represent estimates, bars represent
623	standard errors.
624	AAM: age at menarche; Δ AAM: change in AAM; BMI: body mass index; CAD: coronary artery
625	disease; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein
626	cholesterol; PGS: polygenic score
627	
628	Figure 4: Associations of variation in AAM with risk factors for CAD in the WGHS. PGS-
629	associated ΔAAM showed linear or roughly linear associations with most CAD risk factors and
630	PGS-independent ΔAAM showed mostly non-linear associations with most CAD risk factors.
631	Similar to results in the UK Biobank, hemoglobin A1c, triglycerides and HDL-C showed U-
632	shaped associations with PGS-independent ΔAAM which support conclusions from the primary

633	analyses that dysglycemia, dyslipidemia and central adiposity may mediate the relationship
634	between later AAM and increased risk of CAD. For LDL-C, $n = 22,495$ after excluding those
635	taking cholesterol-lowering medications. Dots represent estimates, bars represent standard errors.
636	AAM: age at menarche; ΔAAM: change in AAM; BMI: body mass index; CAD: coronary artery
637	disease; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein
638	cholesterol; PGS: polygenic score; WGHS: Women's Genome Health Study.
639	
640	Figure 5: Associations of variation in AAM with hazard ratio for risk of CAD in the
641	WGHS. PGS-associated \triangle AAM demonstrated a negative linear association with risk of CAD,
	WGHS. FOS-associated $\Delta AAW demonstrated a negative initial association with fisk of CAD,$
642	similar to the results in the UKBB. PGS-independent ΔAAM demonstrated a reverse-J shaped
642 643	
	similar to the results in the UKBB. PGS-independent ΔAAM demonstrated a reverse-J shaped
643	similar to the results in the UKBB. PGS-independent Δ AAM demonstrated a reverse-J shaped relationship, slightly different from the U-shaped relationship seen in the UK Biobank. Analyses
643 644	similar to the results in the UKBB. PGS-independent Δ AAM demonstrated a reverse-J shaped relationship, slightly different from the U-shaped relationship seen in the UK Biobank. Analyses in the WGHS largely validated the results from the UK Biobank. The different associations of
643 644 645	similar to the results in the UKBB. PGS-independent Δ AAM demonstrated a reverse-J shaped relationship, slightly different from the U-shaped relationship seen in the UK Biobank. Analyses in the WGHS largely validated the results from the UK Biobank. The different associations of PGS-independent Δ AAM driving AAM later with risk of CAD may have been due to differences

TABLES 649

	Change per year in	ncrease in A	AM		
	Negative values of ΔAAM Positive values of ΔAAM		<i>p</i> for difference between slopes		
	Odds ratio (95% CI)	P	Odds ratio (95% CI)	p	
PGS-associated ΔAAM	0.91 (0.83 to 0.99)	3x10 ⁻²	0.92 (0.84 to 1)	0.063	0.87
PGS- independent ΔAAM	0.92 (0.88 to 0.95)	3x10 ⁻⁶	1.11 (1.08 to 1.15)	2x10 ⁻⁹	7x10 ⁻¹⁰
Coronary artery	disease risk factors			1	
	Change per year in	ncrease in A	AM		
	Negative values of	ΔΑΑΜ	Positive values of <i>A</i>	AAM	<i>p</i> for difference between slopes
	Slope (95% CI)	p	Slope (95% CI)	р	
Hemoglobin A1c	e (%)				
PGS-associated ΔAAM	-0.034 (-0.041 to - 0.027)	$<2x10^{-16}$	-0.01 (-0.02 to - 0.006)	3x10 ⁻³	6x10 ⁻⁵
PGS- independent ΔAAM	-0.022 (-0.025 to - 0.019)	<2x10 ⁻¹⁶	0.007 (0.004 to 0.01)	1.3x10 ⁻⁶	<2x10 ⁻¹⁶
Triglycerides (m	g/dL)			1	
PGS-associated ΔAAM	-2.82 (-3.84 to - 1.79)	7x10 ⁻⁸	-2.63 (-3.62 to - 1.64)	2x10 ⁻⁷	0.83
PGS- independent	-4.25 (-4.7 to -3.8)	<2x10 ⁻¹⁶	1.2 (0.78 to 1.62)	2x10 ⁻⁸	<2x10 ⁻¹⁶

PGS-associated ΔAAM	0.90 (0.69-1.11)	$<2x10^{-16}$	0.74 (0.54-0.95)	8x10 ⁻¹³	0.38
PGS- independent ΔAAM	0.85 (0.76-0.95)	<2x10 ⁻¹⁶	-0.28 (-0.37 to - 0.20)	2x10 ⁻¹⁰	$<2x10^{-16}$
Low-density lipo	protein (LDL) chole	esterol (mg/d	L)	1	
	Adjusted for LDL-	lowering med	ications		
PGS-associated ΔAAM	0.27 (-0.15 to 0.69)	2x10 ⁻¹	-0.53 (-0.93 to - 0.12)	1x10 ⁻²	0.026
PGS- independent ΔAAM	-0.46 (-0.65 to - 0.28)	1x10 ⁻⁶	0.067 (-0.11 to 0.24)	0.45	7x10 ⁻⁴
	Including only those	se not taking I	LDL-lowering medica	ations $(n = 1)$	77,542)
PGS-associated ΔAAM	0.14 (-0.31 to 0.59)	0.054	-0.59 (-1.02 to - 0.16)	8x10 ⁻³	0.059
PGS- independent ΔAAM	-0.53 (-0.72 to - 0.33)	3x10 ⁻⁷	0.0065 (-0.18 to 0.19)	0.9	2x10 ⁻³
Systolic blood pr	ressure (mmHg)				
PGS-associated ΔAAM	-0.73 (-0.99 to - 0.47)	4x10 ⁻⁸	-0.71 (-0.96 to - 0.45)	5x10 ⁻⁸	0.91
PGS- independent ΔAAM	-0.69 (-0.81 to - 0.58)	<2x10 ⁻¹⁶	-0.21 (-0.31 to - 0.10)	2x10 ⁻⁴	5x10 ⁻⁷
Diastolic blood p	oressure (mmHg)				
PGS-associated ΔAAM	-0.49 (-0.63 to - 0.34)	5x10 ⁻¹¹	-0.49 (-0.63 to - 0.35)	9 x10 ⁻¹²	0.98
PGS- independent ΔAAM	-0.52 (-0.59 to - 0.46)	<2x10 ⁻¹⁶	-0.14 (-0.20 to - 0.08)	5 x10 ⁻⁶	2x10 ⁻¹²
Body-mass index	x (kg/m ²)	1	1	1	
PGS-associated ΔAAM	-0.98 (-1.05 to - 0.91)	<2x10 ⁻¹⁶	-0.77 (-0.84 to - 0.70)	<2 x10 ⁻¹⁶	4x10 ⁻⁴
PGS- independent	-0.80 (-0.83 to - 0.77)	<2x10 ⁻¹⁶	-0.079 (-0.11 to - 0.051)	4 x10 ⁻⁸	<2x10 ⁻¹⁶

ΔΑΑΜ					
Waist-hip ratio					
PGS-associated ΔAAM	-0.0038 (-0.0047 to -0.0029)	1.1x10 ⁻¹⁵	-0.0029 (-0.0038 to -0.0020)	$2x10^{-10}$	0.28
PGS- independent ΔAAM	-0.0046 (-0.0050 to -0.0042)	<2x10 ⁻¹⁶	0.0016 (0.0012 to 0.0020)	<2x10 ⁻¹⁶	$<2x10^{-16}$

- **Table 1:** Associations of variation in age at menarche with coronary artery disease and its risk
- 652 factors.
- 653 AAM: age at menarche; $\triangle AAM$: change in AAM; PGS: polygenic score

654 FIGURES




Figure 1: Relationships of different sources of variation in age at menarche (AAM) with 656 coronary artery disease (CAD) and CAD risk factors. Variation in AAM was dissected into 657 658 variation associated with common genetic variants (as estimated by a polygenic score for AAM) and variation independent of the polygenic score, then associations of these sources of variation 659 with CAD and CAD risk factors were studied. When associated with common genetic variants, 660 later AAM was associated with a lower risk of CAD and favorable changes in CAD risk factors 661 (blue arrows). However, when occurring independently of the polygenic score, later AAM was 662 associated with higher risk of CAD and unfavorable changes in CAD risk factors (red arrows). 663 The "other factors" causing later AAM independent of the PGS have yet to be identified and 664 could potentially include chronic illness, underweight, and rare genetic variants. 665




Figure 2: Association of variation in AAM with odds of CAD in the UK Biobank. Variation

- 668 in AAM was dissected into variation associated with common genetic variants as estimated by a
- 669 PGS for AAM (PGS-associated ΔAAM) and variation independent of the PGS (PGS-
- 670 independent ΔAAM), then associations of these sources of variation with risk of CAD were
- 671 studied. PGS-associated ΔAAM showed linear or roughly linear associations with CAD whereas
- 672 PGS-independent $\triangle AAM$ showed a U-shaped association with risk of CAD. The different

- associations of positive values of PGS-associated ΔAAM with risk of CAD demonstrates that it
- is not later AAM itself that causes the increased risk of CAD and that the increased risk of CAD
- observed in later AAM is being driven by factors other than common genetic variants and that.
- To achieve bin sizes of ≥ 1000 individuals, the first and last bins for each variable represent the
- group of individuals with $\Delta AAM \le or \ge$ the value listed on the x-axis, respectively. Dots
- 678 represent estimates; bars represent standard errors.
- AAM: age at menarche; \triangle AAM: change in AAM; CAD: coronary artery disease; PGS:
- 680 polygenic score.

PGS-associated ∆AAM






Figure 3: Associations of variation in AAM with risk factors for CAD in the UK Biobank. We observed linear (or roughly linear) relationships between PGS-associated Δ AAM and most CAD risk factors. In contrast, for PGS-independent Δ AAM we observed mostly non-linear relationships with CAD risk factors. The U-shaped relationship of PGS-independent Δ AAM with CAD was mirrored by the relationships with HbA1c, triglycerides, HDL-C, and waist-hip ratio. This raises the possibility that dysglycemia, dyslipidemia and central adiposity may mediate the relationship between later AAM and increased risk of CAD. For LDL-C, n = 177,542 after


- 689 excluding those taking LDL-C lowering medications. Dots represent estimates, bars represent
- 690 standard errors.
- 691 AAM: age at menarche; Δ AAM: change in AAM; BMI: body mass index; CAD: coronary artery
- disease; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein
- 693 cholesterol; PGS: polygenic score







- AAM: age at menarche; ΔAAM: change in AAM; BMI: body mass index; CAD: coronary artery
- disease; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein
- cholesterol; PGS: polygenic score; WGHS: Women's Genome Health Study.



707


708 Figure 5: Associations of variation in AAM with hazard ratio for risk of CAD in the

WGHS. PGS-associated \triangle AAM demonstrated a negative linear association with risk of CAD,


- similar to the results in the UKBB. PGS-independent ΔAAM demonstrated a reverse-J shaped
- relationship, slightly different from the U-shaped relationship seen in the UK Biobank. Analyses
- in the WGHS largely validated the results from the UK Biobank. The different associations of

- 713 PGS-independent Δ AAM driving AAM later with risk of CAD may have been due to differences
- in environmental factors between the two study cohorts.
- AAM: age at menarche; Δ AAM: change in AAM; CAD: coronary artery disease; PGS:
- 716 polygenic score. Dots represent estimates, bars represent standard errors.

717 SUPPLEMENTAL MATERIAL




Supplemental Figure 1: Derivation of PGS-associated and PGS-independent change in age 719 at menarche. Self-reported age at menarche (AAM) was regressed against a polygenic score 720 721 (PGS) for AAM. The green line indicates the regression line for self-reported AAM against PGS, 722 the horizontal dashed line represents the observed AAM at the mean PGS for the cohort, the dots 723 represent two examples of women, the blue dotted arrow represents PGS-associated change in 724 AAM (Δ AAM), and the red dashed arrow represents PGS-independent Δ AAM. For the woman 725 represented by the dot on the left, AAM predicted by the PGS (regression) is below the mean for 726 the cohort, so PGS-associated ΔAAM is negative, and self-reported AAM is above the regression 727 line, so PGS-independent $\triangle AAM$ is positive. For the woman represented by the dot on the right, AAM predicted by the PGS is above the mean for the cohort, so PGS-associated $\triangle AAM$ is 728 729 positive, and self-reported AAM is above the regression line, so PGS-independent Δ AAM is also positive. 730



732 Supplemental Figure 2: Distribution of PGS-associated ΔAAM in the UK Biobank (A),

- 733 PGS-independent ΔAAM in the UK Biobank (B), PGS-associated ΔAAM in the WGHS (C),
- 734 and PGS-independent ΔAAM in the WGHS (D).

AAM: age at menarche; ∆AAM: change in AAM; PGS: polygenic score, WGHS: Women's
Genome Health Study.



- 738 Supplemental Figure 3: Association of variation in age at menarche with coronary artery
- disease in the UK Biobank using a PGS based on a 2014 genome-wide association study meta-
- analysis that did not include data from the UK Biobank.
- AAM: age at menarche; Δ AAM: change in AAM; PGS: polygenic score. Dots represent
- r42 estimates, bars represent standard errors.

	Negative values of	Positive values of ΔΑΑΜ		<i>p</i> for difference between slopes			
Coronary artery disease							
	Odds ratio (95%	р	Odds ratio (95%	р			
	CI)		CI)				
PGS-associated	0.89 (0.77 to 1.04)	0.14	0.98 (0.86 to 1.1)	0.79	0.43		
ΔΑΑΜ							
PGS-	0.91 (0.88 to 0.94)	5×10^{-7}	1.09 (1.06 to	4×10^{-7}	5x10 ⁻⁹		
independent			1.13)				
ΔΑΑΜ							

743

744 **Supplemental Table 1:** Associations between variation in age at menarche and coronary artery

disease using a PGS based on a 2014 genome-wide association study meta-analysis that did not

- include data from the UK Biobank.
- 747 AAM: age at menarche; Δ AAM: change in AAM; PGS: polygenic score